{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T04:01:33Z","timestamp":1792123293022,"version":"4.4.0"},"reference-count":128,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s11033-026-12132-y","type":"journal-article","created":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T11:17:54Z","timestamp":1781781474000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["The role of fibroblast growth factor 21 in diabetes and metabolic dysfunction"],"prefix":"10.1007","volume":"53","author":[{"given":"Ashirvad","family":"Jaiswal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chadani","family":"Nigam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaurish Narayan","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anurag Kumar","family":"Gautam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,18]]},"reference":[{"key":"12132_CR1","doi-asserted-by":"publisher","first-page":"109119","DOI":"10.1016\/j.diabres.2021.109119","volume":"183","author":"H Sun","year":"2021","unstructured":"Sun H, Saeedi P, Karuranga S et al (2021) IDF diabetes atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract 183:109119. https:\/\/doi.org\/10.1016\/j.diabres.2021.109119","journal-title":"Diabetes Res Clin Pract"},{"key":"12132_CR2","doi-asserted-by":"publisher","first-page":"e56674","DOI":"10.7759\/cureus.56674","volume":"16","author":"A Kulkarni","year":"2024","unstructured":"Kulkarni A, Thool AR, Daigavane S (2024) Understanding the clinical relationship between diabetic retinopathy, nephropathy, and neuropathy: A comprehensive. Rev Cureus 16:e56674. https:\/\/doi.org\/10.7759\/cureus.56674","journal-title":"Rev Cureus"},{"key":"12132_CR3","doi-asserted-by":"publisher","unstructured":"(2009) Diagnosis and classification of diabetes mellitus. Diabetes Care 32:S62\u2013S67. https:\/\/doi.org\/10.2337\/dc09-S062","DOI":"10.2337\/dc09-S062"},{"key":"12132_CR4","doi-asserted-by":"publisher","unstructured":"Galicia-Garcia U, Benito-Vicente A, Jebari S et al (2020) Pathophysiology of type 2 diabetes mellitus. Int J Mol Sci 21. https:\/\/doi.org\/10.3390\/ijms21176275","DOI":"10.3390\/ijms21176275"},{"key":"12132_CR5","first-page":"111","volume":"13","author":"S Bastaki","year":"2005","unstructured":"Bastaki S (2005) Diabetes mellitus and its treatment. Int J Diabetes Metab 13:111\u2013134","journal-title":"Int J Diabetes Metab"},{"key":"12132_CR6","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/s0167-4781(00)00067-1","volume":"1492","author":"T Nishimura","year":"2000","unstructured":"Nishimura T, Nakatake Y, Konishi M, Itoh N (2000) Identification of a novel FGF, FGF-21, preferentially expressed in the liver. Biochim Biophys Acta 1492:203\u2013206. https:\/\/doi.org\/10.1016\/s0167-4781(00)00067-1","journal-title":"Biochim Biophys Acta"},{"key":"12132_CR7","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1172\/JCI23606","volume":"115","author":"A Kharitonenkov","year":"2005","unstructured":"Kharitonenkov A, Shiyanova TL, Koester A et al (2005) FGF-21 as a novel metabolic regulator. J Clin Invest 115:1627\u20131635. https:\/\/doi.org\/10.1172\/JCI23606","journal-title":"J Clin Invest"},{"key":"12132_CR8","doi-asserted-by":"publisher","unstructured":"Mart\u00ednez-Garza \u00da, Torres-Oteros D, Yarritu-Gallego A et al (2019) Fibroblast growth factor 21 and the adaptive response to nutritional challenges. Int J Mol Sci 20. https:\/\/doi.org\/10.3390\/ijms20194692","DOI":"10.3390\/ijms20194692"},{"key":"12132_CR9","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1111\/joim.12580","volume":"281","author":"A Kharitonenkov","year":"2017","unstructured":"Kharitonenkov A, DiMarchi R (2017) Fibroblast growth factor 21 night watch: advances and uncertainties in the field. J Intern Med 281:233\u2013246. https:\/\/doi.org\/10.1111\/joim.12580","journal-title":"J Intern Med"},{"key":"12132_CR10","doi-asserted-by":"publisher","first-page":"68","DOI":"10.62347\/PALK2137","volume":"15","author":"P Phan","year":"2024","unstructured":"Phan P, Ternier G, Edirisinghe O, Kumar TKS (2024) Exploring endocrine FGFs - structures, functions and biomedical applications. Int J Biochem Mol Biol 15:68\u201399. https:\/\/doi.org\/10.62347\/PALK2137","journal-title":"Int J Biochem Mol Biol"},{"key":"12132_CR11","doi-asserted-by":"publisher","first-page":"6120","DOI":"10.1074\/jbc.C500457200","volume":"281","author":"H Kurosu","year":"2006","unstructured":"Kurosu H, Ogawa Y, Miyoshi M et al (2006) Regulation of fibroblast growth factor-23 signaling by klotho. J Biol Chem 281:6120\u20136123. https:\/\/doi.org\/10.1074\/jbc.C500457200","journal-title":"J Biol Chem"},{"key":"12132_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/jcp.21357","volume":"215","author":"A Kharitonenkov","year":"2008","unstructured":"Kharitonenkov A, Dunbar JD, Bina HA et al (2008) FGF-21\/FGF-21 receptor interaction and activation is determined by betaKlotho. J Cell Physiol 215:1\u20137. https:\/\/doi.org\/10.1002\/jcp.21357","journal-title":"J Cell Physiol"},{"key":"12132_CR13","doi-asserted-by":"publisher","first-page":"9175","DOI":"10.1074\/jbc.M116.767590","volume":"292","author":"T Goto","year":"2017","unstructured":"Goto T, Hirata M, Aoki Y et al (2017) The hepatokine FGF21 is crucial for peroxisome proliferator-activated receptor-\u03b1 agonist-induced amelioration of metabolic disorders in obese mice. J Biol Chem 292:9175\u20139190. https:\/\/doi.org\/10.1074\/jbc.M116.767590","journal-title":"J Biol Chem"},{"key":"12132_CR14","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1146\/annurev-nutr-071816-064800","volume":"38","author":"LD BonDurant","year":"2018","unstructured":"BonDurant LD, Potthoff MJ (2018) Fibroblast growth factor 21: A versatile regulator of metabolic homeostasis. Annu Rev Nutr 38:173\u2013196. https:\/\/doi.org\/10.1146\/annurev-nutr-071816-064800","journal-title":"Annu Rev Nutr"},{"key":"12132_CR15","doi-asserted-by":"publisher","first-page":"3281","DOI":"10.2147\/DMSO.S317096","volume":"14","author":"W Lin","year":"2021","unstructured":"Lin W, Zhang T, Zhou Y et al (2021) Advances in biological functions and clinical studies of FGF21. Diabetes. Metab Syndr Obes Targets Ther 14:3281\u20133290. https:\/\/doi.org\/10.2147\/DMSO.S317096","journal-title":"Metab Syndr Obes Targets Ther"},{"key":"12132_CR16","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1038\/s41574-020-0386-0","volume":"16","author":"L Geng","year":"2020","unstructured":"Geng L, Lam KSL, Xu A (2020) The therapeutic potential of FGF21 in metabolic diseases: from bench to clinic. Nat Rev Endocrinol 16:654\u2013667. https:\/\/doi.org\/10.1038\/s41574-020-0386-0","journal-title":"Nat Rev Endocrinol"},{"key":"12132_CR17","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s44324-025-00062-5","volume":"3","author":"P Aldiss","year":"2025","unstructured":"Aldiss P, Nielsen MH, Burm H et al (2025) FGF21 deletion mildly exacerbates hepatic dysfunction in GAN diet and alcohol fed rats. npj Metab Heal Dis 3:21. https:\/\/doi.org\/10.1038\/s44324-025-00062-5","journal-title":"npj Metab Heal Dis"},{"key":"12132_CR18","doi-asserted-by":"publisher","first-page":"1619462","DOI":"10.3389\/fendo.2025.1619462","volume":"16","author":"H Zhang","year":"2025","unstructured":"Zhang H, Zhu R, Sun Q, Du L (2025) Research progress on the role of FGF21 in insulin resistance. Front Endocrinol (Lausanne) 16:1619462. https:\/\/doi.org\/10.3389\/fendo.2025.1619462","journal-title":"Front Endocrinol (Lausanne)"},{"key":"12132_CR19","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.cmet.2013.08.005","volume":"18","author":"G Gaich","year":"2013","unstructured":"Gaich G, Chien JY, Fu H et al (2013) The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes. Cell Metab 18:333\u2013340. https:\/\/doi.org\/10.1016\/j.cmet.2013.08.005","journal-title":"Cell Metab"},{"key":"12132_CR20","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1124\/jpet.123.001618","volume":"387","author":"M Rosenstock","year":"2023","unstructured":"Rosenstock M, Tseng L, Pierce A et al (2023) The Novel GlycoPEGylated FGF21 Analog pegozafermin activates human FGF receptors and improves metabolic and liver outcomes in diabetic monkeys and healthy human volunteers. J Pharmacol Exp Ther 387:204\u2013213. https:\/\/doi.org\/10.1124\/jpet.123.001618","journal-title":"J Pharmacol Exp Ther"},{"key":"12132_CR21","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/j.jconrel.2020.05.036","volume":"324","author":"H Watanabe","year":"2020","unstructured":"Watanabe H, Miyahisa M, Chikamatsu M et al (2020) Development of a long acting FGF21 analogue-albumin fusion protein and its anti-diabetic effects. J Control Release 324:522\u2013531. https:\/\/doi.org\/10.1016\/j.jconrel.2020.05.036","journal-title":"J Control Release"},{"key":"12132_CR22","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.tem.2024.02.001","volume":"35","author":"ZSW Chui","year":"2024","unstructured":"Chui ZSW, Shen Q, Xu A (2024) Current status and future perspectives of FGF21 analogues in clinical trials. Trends Endocrinol Metab 35:371\u2013384. https:\/\/doi.org\/10.1016\/j.tem.2024.02.001","journal-title":"Trends Endocrinol Metab"},{"key":"12132_CR23","doi-asserted-by":"publisher","first-page":"2781","DOI":"10.2337\/db10-0193","volume":"59","author":"FM Fisher","year":"2010","unstructured":"Fisher FM, Chui PC, Antonellis PJ et al (2010) Obesity is a fibroblast growth factor 21 (FGF21)-resistant state. Diabetes 59:2781\u20132789. https:\/\/doi.org\/10.2337\/db10-0193","journal-title":"Diabetes"},{"key":"12132_CR24","doi-asserted-by":"publisher","unstructured":"Qiang W, Shen T, Noman M et al (2021) Fibroblast growth factor 21 augments autophagy and reduces apoptosis in damaged liver to improve tissue regeneration in zebrafish. 9:1\u201312. https:\/\/doi.org\/10.3389\/fcell.2021.756743","DOI":"10.3389\/fcell.2021.756743"},{"key":"12132_CR25","first-page":"1308","volume":"11","author":"H Jia","year":"2018","unstructured":"Jia H, Cheng J, Zhou Q et al (2018) Fibroblast growth factor 21 attenuates inflammation and oxidative stress in atherosclerotic rat via enhancing the Nrf1-ARE signaling pathway. Int J Clin Exp Pathol 11:1308\u20131317","journal-title":"Int J Clin Exp Pathol"},{"key":"12132_CR26","doi-asserted-by":"publisher","first-page":"107634","DOI":"10.1016\/j.intimp.2021.107634","volume":"96","author":"K Kang","year":"2021","unstructured":"Kang K, Xia A, Meng F et al (2021) FGF21 alleviates chronic inflammatory injury in the aging process through modulating polarization of macrophages. Int Immunopharmacol 96:107634. https:\/\/doi.org\/10.1016\/j.intimp.2021.107634","journal-title":"Int Immunopharmacol"},{"key":"12132_CR27","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.yexcr.2016.06.020","volume":"346","author":"X-M Wang","year":"2016","unstructured":"Wang X-M, Xiao H, Liu L-L et al (2016) FGF21 represses cerebrovascular aging via improving mitochondrial biogenesis and inhibiting p53 signaling pathway in an AMPK-dependent manner. Exp Cell Res 346:147\u2013156. https:\/\/doi.org\/10.1016\/j.yexcr.2016.06.020","journal-title":"Exp Cell Res"},{"key":"12132_CR28","doi-asserted-by":"publisher","first-page":"200","DOI":"10.3177\/jnsv.64.200","volume":"64","author":"R Maruyama","year":"2018","unstructured":"Maruyama R, Shimizu M, Hashidume T et al (2018) FGF21 Alleviates hepatic endoplasmic reticulum stress under physiological conditions. J Nutr Sci Vitaminol (Tokyo) 64:200\u2013208. https:\/\/doi.org\/10.3177\/jnsv.64.200","journal-title":"J Nutr Sci Vitaminol (Tokyo)"},{"key":"12132_CR29","doi-asserted-by":"publisher","first-page":"eabn7105","DOI":"10.1126\/sciadv.abn7105","volume":"8","author":"M Croon","year":"2025","unstructured":"Croon M, Szczepanowska K, Popovic M et al (2025) FGF21 modulates mitochondrial stress response in cardiomyocytes only under mild mitochondrial dysfunction. Sci Adv 8:eabn7105. https:\/\/doi.org\/10.1126\/sciadv.abn7105","journal-title":"Sci Adv"},{"key":"12132_CR30","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1097\/MOL.0000000000000960","volume":"36","author":"DR Barros","year":"2025","unstructured":"Barros DR, Hegele RA (2025) Fibroblast growth factor 21: update on genetics and molecular biology. Curr Opin Lipidol 36:88\u201395. https:\/\/doi.org\/10.1097\/MOL.0000000000000960","journal-title":"Curr Opin Lipidol"},{"key":"12132_CR31","doi-asserted-by":"publisher","unstructured":"Hemat Jouy S, Mohan S, Scichilone G et al (2024) Adipokines in the crosstalk between adipose tissues and other organs: implications in cardiometabolic diseases. Biomedicines 12. https:\/\/doi.org\/10.3390\/biomedicines12092129","DOI":"10.3390\/biomedicines12092129"},{"key":"12132_CR32","doi-asserted-by":"publisher","unstructured":"Li D, Fu G, Tu R et al (2019) High \u2013 efficiency expression and secretion of human FGF21 in Bacillus subtilis by intercalation of a mini \u2013 cistron cassette and combinatorial optimization of cell regulatory components. Microb Cell Fact 1\u201315. https:\/\/doi.org\/10.1186\/s12934-019-1066-4","DOI":"10.1186\/s12934-019-1066-4"},{"key":"12132_CR33","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/bs.vh.2016.02.008","volume":"101","author":"DM Kilkenny","year":"2016","unstructured":"Kilkenny DM, Rocheleau JV (2016) The FGF21 receptor signaling complex: Klotho\u03b2, FGFR1c, and other regulatory interactions. Vitam Horm 101:17\u201358. https:\/\/doi.org\/10.1016\/bs.vh.2016.02.008","journal-title":"Vitam Horm"},{"key":"12132_CR34","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.cmet.2007.05.003","volume":"5","author":"T Inagaki","year":"2007","unstructured":"Inagaki T, Dutchak P, Zhao G et al (2007) Endocrine regulation of the fasting response by PPAR\u03b1-mediated induction of fibroblast growth factor 21. Cell Metab 5:415\u2013425. https:\/\/doi.org\/10.1016\/j.cmet.2007.05.003","journal-title":"Cell Metab"},{"key":"12132_CR35","doi-asserted-by":"publisher","first-page":"5825","DOI":"10.3390\/ijms26125825","volume":"26","author":"EY Kim","year":"2025","unstructured":"Kim EY, Lee JM (2025) Liver metabolism at the crossroads: The reciprocal control of nutrient-sensing nuclear receptors and autophagy. Int J Mol Sci 26:5825","journal-title":"Int J Mol Sci"},{"key":"12132_CR36","doi-asserted-by":"publisher","first-page":"77","DOI":"10.3389\/fendo.2016.00077","volume":"7","author":"PJ Antonellis","year":"2016","unstructured":"Antonellis PJ, Hayes MP, Adams AC (2016) Fibroblast growth factor 21-null mice do not exhibit an impaired response to fasting. Front Endocrinol (Lausanne) 7:77. https:\/\/doi.org\/10.3389\/fendo.2016.00077","journal-title":"Front Endocrinol (Lausanne)"},{"key":"12132_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/jcp.20847","volume":"210","author":"JS Moyers","year":"2007","unstructured":"Moyers JS, Shiyanova TL, Mehrbod F et al (2007) Molecular determinants of FGF-21 activity-synergy and cross-talk with PPARgamma signaling. J Cell Physiol 210:1\u20136. https:\/\/doi.org\/10.1002\/jcp.20847","journal-title":"J Cell Physiol"},{"key":"12132_CR38","doi-asserted-by":"publisher","first-page":"109331","DOI":"10.1016\/j.celrep.2021.109331","volume":"35","author":"M Abu-Odeh","year":"2021","unstructured":"Abu-Odeh M, Zhang Y, Reilly SM et al (2021) FGF21 promotes thermogenic gene expression as an autocrine factor in adipocytes. Cell Rep 35:109331. https:\/\/doi.org\/10.1016\/j.celrep.2021.109331","journal-title":"Cell Rep"},{"key":"12132_CR39","doi-asserted-by":"publisher","first-page":"101","DOI":"10.2337\/db13-0710","volume":"63","author":"BA Omar","year":"2013","unstructured":"Omar BA, Andersen B, Hald J et al (2013) Fibroblast growth factor 21 (FGF21) and glucagon-like peptide 1 contribute to diabetes resistance in glucagon receptor\u2013deficient mice. Diabetes 63:101\u2013110. https:\/\/doi.org\/10.2337\/db13-0710","journal-title":"Diabetes"},{"key":"12132_CR40","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.cellsig.2017.08.009","volume":"40","author":"A Salminen","year":"2017","unstructured":"Salminen A, Kaarniranta K, Kauppinen A (2017) Integrated stress response stimulates FGF21 expression: Systemic enhancer of longevity. Cell Signal 40:10\u201321. https:\/\/doi.org\/10.1016\/j.cellsig.2017.08.009","journal-title":"Cell Signal"},{"key":"12132_CR41","doi-asserted-by":"publisher","first-page":"454","DOI":"10.2337\/db25-0655","volume":"75","author":"Y Sun","year":"2026","unstructured":"Sun Y, Zhang J, Su Y et al (2026) Downregulation of hepatic PPA1 protects against obesity by elevating FGF21 production via eIF2\u03b1 phosphorylation. Diabetes 75:454\u2013467. https:\/\/doi.org\/10.2337\/db25-0655","journal-title":"Diabetes"},{"key":"12132_CR42","doi-asserted-by":"publisher","unstructured":"Liu L, Ito M, Sakai S et al (2024) FGF21 upregulation by hepatitis C virus via the eIF2\u03b1-ATF4 pathway: implications for interferon signaling suppression and TRIM31-mediated TSC degradation. Front Microbiol Volume 15. https:\/\/doi.org\/10.3389\/fmicb.2024.1456108","DOI":"10.3389\/fmicb.2024.1456108"},{"key":"12132_CR43","doi-asserted-by":"crossref","unstructured":"Li X, Li Y, Hao Q et al (2024) Metabolic mechanisms orchestrated by Sirtuin family to modulate inflammatory responses. Front Immunol Volume 15","DOI":"10.3389\/fimmu.2024.1448535"},{"key":"12132_CR44","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1016\/j.molmet.2016.07.003","volume":"5","author":"MA S\u00e1nchez-Garrido","year":"2016","unstructured":"S\u00e1nchez-Garrido MA, Habegger KM, Clemmensen C et al (2016) Fibroblast activation protein (FAP) as a novel metabolic target. Mol Metab 5:1015\u20131024. https:\/\/doi.org\/10.1016\/j.molmet.2016.07.003","journal-title":"Mol Metab"},{"key":"12132_CR45","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1038\/s42255-021-00354-2","volume":"3","author":"KH Flippo","year":"2021","unstructured":"Flippo KH, Potthoff MJ (2021) Metabolic messengers: FGF21. Nat Metab 3:309\u2013317. https:\/\/doi.org\/10.1038\/s42255-021-00354-2","journal-title":"Nat Metab"},{"key":"12132_CR46","doi-asserted-by":"publisher","first-page":"5928","DOI":"10.7150\/ijbs.76924","volume":"18","author":"Y Sui","year":"2022","unstructured":"Sui Y, Chen J (2022) Hepatic FGF21: Its emerging role in inter-organ crosstalk and cancers. Int J Biol Sci 18:5928\u20135942. https:\/\/doi.org\/10.7150\/ijbs.76924","journal-title":"Int J Biol Sci"},{"key":"12132_CR47","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.cmet.2007.05.003","volume":"5","author":"T Inagaki","year":"2007","unstructured":"Inagaki T, Dutchak P, Zhao G et al (2007) Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21. Cell Metab 5:415\u2013425. https:\/\/doi.org\/10.1016\/j.cmet.2007.05.003","journal-title":"Cell Metab"},{"key":"12132_CR48","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.cmet.2008.06.014","volume":"8","author":"C G\u00e4lman","year":"2008","unstructured":"G\u00e4lman C, Lund\u00e5sen T, Kharitonenkov A et al (2008) The circulating metabolic regulator FGF21 is induced by prolonged fasting and PPARalpha activation in man. Cell Metab 8:169\u2013174. https:\/\/doi.org\/10.1016\/j.cmet.2008.06.014","journal-title":"Cell Metab"},{"key":"12132_CR49","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.mce.2011.05.003","volume":"342","author":"Y Zhang","year":"2011","unstructured":"Zhang Y, Lei T, Huang JF et al (2011) The link between fibroblast growth factor 21 and sterol regulatory element binding protein 1c during lipogenesis in hepatocytes. Mol Cell Endocrinol 342:41\u201347. https:\/\/doi.org\/10.1016\/j.mce.2011.05.003","journal-title":"Mol Cell Endocrinol"},{"key":"12132_CR50","doi-asserted-by":"publisher","first-page":"3678","DOI":"10.1038\/s41467-025-58836-w","volume":"16","author":"N Kobayashi","year":"2025","unstructured":"Kobayashi N, Okazaki Y, Iwane A et al (2025) Activin B improves glucose metabolism via induction of Fgf21 and hepatic glucagon resistance. Nat Commun 16:3678. https:\/\/doi.org\/10.1038\/s41467-025-58836-w","journal-title":"Nat Commun"},{"key":"12132_CR51","doi-asserted-by":"publisher","first-page":"2274","DOI":"10.1007\/s00125-017-4389-x","volume":"60","author":"T Laeger","year":"2017","unstructured":"Laeger T, Baumeier C, Wilhelmi I et al (2017) FGF21 improves glucose homeostasis in an obese diabetes-prone mouse model independent of body fat changes. Diabetologia 60:2274\u20132284. https:\/\/doi.org\/10.1007\/s00125-017-4389-x","journal-title":"Diabetologia"},{"key":"12132_CR52","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1038\/s41467-017-02677-9","volume":"9","author":"H Li","year":"2018","unstructured":"Li H, Wu G, Fang Q et al (2018) Fibroblast growth factor 21 increases insulin sensitivity through specific expansion of subcutaneous fat. Nat Commun 9:272. https:\/\/doi.org\/10.1038\/s41467-017-02677-9","journal-title":"Nat Commun"},{"key":"12132_CR53","doi-asserted-by":"publisher","first-page":"736","DOI":"10.2119\/molmed.2011.00075","volume":"17","author":"DV Chartoumpekis","year":"2011","unstructured":"Chartoumpekis DV, Habeos IG, Ziros PG et al (2011) Brown adipose tissue responds to cold and adrenergic stimulation by induction of FGF21. Mol Med 17:736\u2013740. https:\/\/doi.org\/10.2119\/molmed.2011.00075","journal-title":"Mol Med"},{"key":"12132_CR54","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1016\/j.cmet.2017.03.005","volume":"25","author":"LD BonDurant","year":"2017","unstructured":"BonDurant LD, Ameka M, Naber MC et al (2017) FGF21 regulates metabolism through adipose-dependent and -independent mechanisms. Cell Metab 25:935\u2013944e4. https:\/\/doi.org\/10.1016\/j.cmet.2017.03.005","journal-title":"Cell Metab"},{"key":"12132_CR55","doi-asserted-by":"crossref","unstructured":"Chen Z, Yang L, Liu Y et al (2022) The potential function and clinical application of FGF21 in metabolic diseases. Front Pharmacol Volume 13","DOI":"10.3389\/fphar.2022.1089214"},{"key":"12132_CR56","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1038\/nm.3249","volume":"19","author":"AL Bookout","year":"2013","unstructured":"Bookout AL, de Groot MHM, Owen BM et al (2013) FGF21 regulates metabolism and circadian behavior by acting on the nervous system. Nat Med 19:1147\u20131152. https:\/\/doi.org\/10.1038\/nm.3249","journal-title":"Nat Med"},{"key":"12132_CR57","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.cmet.2015.12.008","volume":"23","author":"S Talukdar","year":"2016","unstructured":"Talukdar S, Owen BM, Song P et al (2016) FGF21 regulates sweet and alcohol preference. Cell Metab 23:344\u2013349. https:\/\/doi.org\/10.1016\/j.cmet.2015.12.008","journal-title":"Cell Metab"},{"key":"12132_CR58","doi-asserted-by":"publisher","first-page":"103938","DOI":"10.1016\/j.jtherbio.2024.103938","volume":"124","author":"PKT Chau","year":"2024","unstructured":"Chau PKT, Ryan E, Dalen KT, Haugen F (2024) Timing of acute cold exposure determines UCP1 and FGF21 expression - Possible interactions between the thermal environment, thermoregulatory responses, and peripheral clocks. J Therm Biol 124:103938. https:\/\/doi.org\/10.1016\/j.jtherbio.2024.103938","journal-title":"J Therm Biol"},{"key":"12132_CR59","doi-asserted-by":"publisher","first-page":"e70657","DOI":"10.1111\/cns.70657","volume":"31","author":"J Chen","year":"2025","unstructured":"Chen J, Liu B, Yao X et al (2025) AMPK\/SIRT1\/PGC-1\u03b1 signaling pathway: molecular mechanisms and targeted strategies from energy homeostasis regulation to disease therapy. CNS Neurosci Ther 31:e70657. https:\/\/doi.org\/10.1111\/cns.70657","journal-title":"CNS Neurosci Ther"},{"key":"12132_CR60","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1093\/ageing\/afab178","volume":"50","author":"E Roh","year":"2021","unstructured":"Roh E, Hwang SY, Yoo HJ et al (2021) Association of plasma FGF21 levels with muscle mass and muscle strength in a national multicentre cohort study: Korean Frailty and Aging Cohort Study. Age Ageing 50:1971\u20131978. https:\/\/doi.org\/10.1093\/ageing\/afab178","journal-title":"Age Ageing"},{"key":"12132_CR61","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.apsb.2012.06.011","volume":"2","author":"X Ge","year":"2012","unstructured":"Ge X, Wang Y, Lam KSL, Xu A (2012) Metabolic actions of FGF21: molecular mechanisms and therapeutic implications. Acta Pharm Sin B 2:350\u2013357. https:\/\/doi.org\/10.1016\/j.apsb.2012.06.011","journal-title":"Acta Pharm Sin B"},{"key":"12132_CR62","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/j.freeradbiomed.2024.09.017","volume":"224","author":"Q Chen","year":"2024","unstructured":"Chen Q, Cheng W, Zhang J et al (2024) Fibroblast growth factor 21 improves insulin sensitivity by modulating the bile acid-gut microbiota axis in type \u2161 diabetic mice. Free Radic Biol Med 224:600\u2013617. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2024.09.017","journal-title":"Free Radic Biol Med"},{"key":"12132_CR63","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1093\/jmcb\/mjw013","volume":"8","author":"X Hui","year":"2016","unstructured":"Hui X, Feng T, Liu Q et al (2016) The FGF21\u2013adiponectin axis in controlling energy and vascular homeostasis. J Mol Cell Biol 8:110\u2013119. https:\/\/doi.org\/10.1093\/jmcb\/mjw013","journal-title":"J Mol Cell Biol"},{"key":"12132_CR64","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/j.cmet.2013.03.019","volume":"17","author":"WL Holland","year":"2013","unstructured":"Holland WL, Adams AC, Brozinick JT et al (2013) An FGF21-adiponectin-ceramide axis controls energy expenditure and insulin action in mice. Cell Metab 17:790\u2013797. https:\/\/doi.org\/10.1016\/j.cmet.2013.03.019","journal-title":"Cell Metab"},{"key":"12132_CR65","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1002\/oby.22376","volume":"27","author":"N Wang","year":"2019","unstructured":"Wang N, Zhao T-T, Li S-M et al (2019) Fibroblast growth factor 21 exerts its anti-inflammatory effects on multiple cell types of adipose tissue in obesity. Obes (Silver Spring) 27:399\u2013408. https:\/\/doi.org\/10.1002\/oby.22376","journal-title":"Obes (Silver Spring)"},{"key":"12132_CR66","doi-asserted-by":"publisher","first-page":"e0184907","DOI":"10.1371\/journal.pone.0184907","volume":"12","author":"NJ Darling","year":"2017","unstructured":"Darling NJ, Balmanno K, Cook SJ (2017) ERK1\/2 signalling protects against apoptosis following endoplasmic reticulum stress but cannot provide long-term protection against BAX\/BAK-independent cell death. PLoS ONE 12:e0184907. https:\/\/doi.org\/10.1371\/journal.pone.0184907","journal-title":"PLoS ONE"},{"key":"12132_CR67","doi-asserted-by":"publisher","unstructured":"Erickson A (2017) The regulation of FGF21 gene expression by metabolic factors and nutrients. 30:1\u201314. https:\/\/doi.org\/10.1515\/hmbci-2016-0016","DOI":"10.1515\/hmbci-2016-0016"},{"key":"12132_CR68","doi-asserted-by":"publisher","unstructured":"Li E, Wang T, Wang F et al (2015) FGF21 protects against ox-LDL induced apoptosis through suppressing CHOP expression in THP1 macrophage derived foam cells. 1\u20137. https:\/\/doi.org\/10.1186\/s12872-015-0077-2","DOI":"10.1186\/s12872-015-0077-2"},{"key":"12132_CR69","doi-asserted-by":"crossref","unstructured":"Tezze C, Romanello V, Sandri M (2019) FGF21 as modulator of metabolism in health and disease. Front Physiol Volume 10","DOI":"10.3389\/fphys.2019.00419"},{"key":"12132_CR70","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1007\/s00125-014-3475-6","volume":"58","author":"SH Kim","year":"2015","unstructured":"Kim SH, Kim KH, Kim H-K et al (2015) Fibroblast growth factor 21 participates in adaptation to endoplasmic reticulum stress and attenuates obesity-induced hepatic metabolic stress. Diabetologia 58:809\u2013818. https:\/\/doi.org\/10.1007\/s00125-014-3475-6","journal-title":"Diabetologia"},{"key":"12132_CR71","doi-asserted-by":"publisher","first-page":"12553","DOI":"10.1073\/pnas.1006962107","volume":"107","author":"MDL Chau","year":"2010","unstructured":"Chau MDL, Gao J, Yang Q et al (2010) Fibroblast growth factor 21 regulates energy metabolism by activating the AMPK-SIRT1-PGC-1alpha pathway. Proc Natl Acad Sci U S A 107:12553\u201312558. https:\/\/doi.org\/10.1073\/pnas.1006962107","journal-title":"Proc Natl Acad Sci U S A"},{"key":"12132_CR72","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1007\/s00125-022-05822-2","volume":"66","author":"X Cui","year":"2023","unstructured":"Cui X, Feng J, Wei T et al (2023) Pancreatic alpha cell glucagon-liver FGF21 axis regulates beta cell regeneration in a mouse model of type 2 diabetes. Diabetologia 66:535\u2013550. https:\/\/doi.org\/10.1007\/s00125-022-05822-2","journal-title":"Diabetologia"},{"key":"12132_CR73","doi-asserted-by":"publisher","first-page":"101064","DOI":"10.1016\/j.gendis.2023.06.033","volume":"11","author":"S Li","year":"2024","unstructured":"Li S, Zou T, Chen J et al (2024) Fibroblast growth factor 21: An emerging pleiotropic regulator of lipid metabolism and the metabolic network. Genes Dis 11:101064. https:\/\/doi.org\/10.1016\/j.gendis.2023.06.033","journal-title":"Genes Dis"},{"key":"12132_CR74","doi-asserted-by":"publisher","first-page":"250","DOI":"10.2337\/db08-0392","volume":"58","author":"J Xu","year":"2009","unstructured":"Xu J, Lloyd DJ, Hale C et al (2009) Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice. Diabetes 58:250\u2013259. https:\/\/doi.org\/10.2337\/db08-0392","journal-title":"Diabetes"},{"key":"12132_CR75","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.cmet.2016.01.006","volume":"23","author":"C Schlein","year":"2016","unstructured":"Schlein C, Talukdar S, Heine M et al (2016) FGF21 lowers plasma triglycerides by accelerating lipoprotein catabolism in white and brown adipose tissues. Cell Metab 23:441\u2013453. https:\/\/doi.org\/10.1016\/j.cmet.2016.01.006","journal-title":"Cell Metab"},{"key":"12132_CR76","doi-asserted-by":"publisher","first-page":"967375","DOI":"10.3389\/fmed.2022.967375","volume":"9","author":"K Falamarzi","year":"2022","unstructured":"Falamarzi K, Malekpour M, Tafti MF et al (2022) The role of FGF21 and its analogs on liver associated diseases. Front Med 9:967375. https:\/\/doi.org\/10.3389\/fmed.2022.967375","journal-title":"Front Med"},{"key":"12132_CR77","doi-asserted-by":"publisher","first-page":"2674","DOI":"10.1091\/mbc.e05-07-0659","volume":"17","author":"Y Ohsaki","year":"2006","unstructured":"Ohsaki Y, Cheng J, Fujita A et al (2006) Cytoplasmic lipid droplets are sites of convergence of proteasomal and autophagic degradation of apolipoprotein B. Mol Biol Cell 17:2674\u20132683. https:\/\/doi.org\/10.1091\/mbc.e05-07-0659","journal-title":"Mol Biol Cell"},{"key":"12132_CR78","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1038\/s41467-020-14384-z","volume":"11","author":"S Byun","year":"2020","unstructured":"Byun S, Seok S, Kim Y-C et al (2020) Fasting-induced FGF21 signaling activates hepatic autophagy and lipid degradation via JMJD3 histone demethylase. Nat Commun 11:807. https:\/\/doi.org\/10.1038\/s41467-020-14384-z","journal-title":"Nat Commun"},{"key":"12132_CR79","doi-asserted-by":"publisher","first-page":"G378","DOI":"10.1152\/ajpgi.00157.2022","volume":"324","author":"MH Nielsen","year":"2023","unstructured":"Nielsen MH, Gillum MP, Vrang N et al (2023) Hepatoprotective effects of the long-acting fibroblast growth factor 21 analog PF-05231023 in the GAN diet-induced obese and biopsy-confirmed mouse model of nonalcoholic steatohepatitis. Am J Physiol Gastrointest Liver Physiol 324:G378\u2013G388. https:\/\/doi.org\/10.1152\/ajpgi.00157.2022","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"12132_CR80","doi-asserted-by":"crossref","unstructured":"Lin S, Tang L, Xu N (2025) Research progress and strategy of FGF21 for skin wound healing. Front Med Volume 12","DOI":"10.3389\/fmed.2025.1510691"},{"key":"12132_CR81","doi-asserted-by":"publisher","first-page":"22","DOI":"10.4093\/dmj.2016.40.1.22","volume":"40","author":"L Jin","year":"2016","unstructured":"Jin L, Lin Z, Xu A (2016) Fibroblast Growth Factor 21 Protects against Atherosclerosis via Fine-Tuning the Multiorgan Crosstalk. Diabetes Metab J 40:22\u201331. https:\/\/doi.org\/10.4093\/dmj.2016.40.1.22","journal-title":"Diabetes Metab J"},{"key":"12132_CR82","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.intimp.2016.05.026","volume":"38","author":"Y Yu","year":"2016","unstructured":"Yu Y, He J, Li S et al (2016) Fibroblast growth factor 21 (FGF21) inhibits macrophage-mediated inflammation by activating Nrf2 and suppressing the NF-\u03baB signaling pathway. Int Immunopharmacol 38:144\u2013152. https:\/\/doi.org\/10.1016\/j.intimp.2016.05.026","journal-title":"Int Immunopharmacol"},{"key":"12132_CR83","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1002\/jcp.29942","volume":"236","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Jiang K, Xie G et al (2021) FGF21 impedes peripheral myelin development by stimulating p38 MAPK\/c-Jun axis. J Cell Physiol 236:1345\u20131361. https:\/\/doi.org\/10.1002\/jcp.29942","journal-title":"J Cell Physiol"},{"key":"12132_CR84","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1042\/CS20190093","volume":"133","author":"T Xie","year":"2019","unstructured":"Xie T, So Y, Li XY, Leung PS (2019) Fibroblast growth factor 21 protects against lipotoxicity-induced pancreatic \u03b2-cell dysfunction via regulation of AMPK signaling and lipid metabolism. Clin Sci 133:2029\u20132044. https:\/\/doi.org\/10.1042\/CS20190093","journal-title":"Clin Sci"},{"key":"12132_CR85","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1055\/a-1778-4159","volume":"54","author":"E Szczepa\u0144ska","year":"2022","unstructured":"Szczepa\u0144ska E, Gietka-Czernel M (2022) FGF21: A novel regulator of glucose and lipid metabolism and whole-body energy balance. Horm Metab Res = Horm und Stoffwechselforsch = Horm Metab 54:203\u2013211. https:\/\/doi.org\/10.1055\/a-1778-4159","journal-title":"Horm Metab Res = Horm und Stoffwechselforsch = Horm Metab"},{"key":"12132_CR86","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1038\/nm.3250","volume":"19","author":"BM Owen","year":"2013","unstructured":"Owen BM, Bookout AL, Ding X et al (2013) FGF21 contributes to neuroendocrine control of female reproduction. Nat Med 19:1153\u20131156. https:\/\/doi.org\/10.1038\/nm.3250","journal-title":"Nat Med"},{"key":"12132_CR87","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s00011-019-01222-2","volume":"68","author":"L Mutsnaini","year":"2019","unstructured":"Mutsnaini L, Kim C-S, Kim J et al (2019) Fibroblast growth factor 21 deficiency aggravates obesity-induced hypothalamic inflammation and impairs thermogenic response. Inflamm Res Off J Eur Histamine Res Soc [et al] 68:351\u2013358. https:\/\/doi.org\/10.1007\/s00011-019-01222-2","journal-title":"Inflamm Res Off J Eur Histamine Res Soc [et al]"},{"key":"12132_CR88","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.redox.2016.12.024","volume":"11","author":"M\u00c1 G\u00f3mez-S\u00e1mano","year":"2017","unstructured":"G\u00f3mez-S\u00e1mano M\u00c1, Grajales-G\u00f3mez M, Zuarth-V\u00e1zquez JM et al (2017) Fibroblast growth factor 21 and its novel association with oxidative stress. Redox Biol 11:335\u2013341. https:\/\/doi.org\/10.1016\/j.redox.2016.12.024","journal-title":"Redox Biol"},{"key":"12132_CR89","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1111\/dom.16089","volume":"27","author":"M Moreno-Lopez","year":"2025","unstructured":"Moreno-Lopez M, Louvet I, Delalleau N et al (2025) The role of the glucagon-FGF21 axis in improving beta cell function during glucose intolerance and SGLT2 inhibition. Diabetes Obes Metab 27:885\u2013898. https:\/\/doi.org\/10.1111\/dom.16089","journal-title":"Diabetes Obes Metab"},{"key":"12132_CR90","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s00109-016-1477-1","volume":"95","author":"A Salminen","year":"2017","unstructured":"Salminen A, Kauppinen A, Kaarniranta K (2017) FGF21 activates AMPK signaling: impact on metabolic regulation and the aging process. J Mol Med 95:123\u2013131. https:\/\/doi.org\/10.1007\/s00109-016-1477-1","journal-title":"J Mol Med"},{"key":"12132_CR91","doi-asserted-by":"crossref","unstructured":"Zhao Z, Cui X, Liao Z (2023) Mechanism of fibroblast growth factor 21 in cardiac remodeling. Front Cardiovasc Med Volume 10","DOI":"10.3389\/fcvm.2023.1202730"},{"key":"12132_CR92","doi-asserted-by":"publisher","unstructured":"Planavila A, Redondo I, Hondares E et al (2013) Fibroblast growth factor 21 protects against cardiac hypertrophy in mice. Nat Commun 4. https:\/\/doi.org\/10.1038\/ncomms3019","DOI":"10.1038\/ncomms3019"},{"key":"12132_CR93","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fonc.2022.832804","volume":"12","author":"J Kim","year":"2022","unstructured":"Kim J, Lee S, Lee MS (2022) Suppressive effect of autocrine FGF21 on autophagy-deficient hepatic tumorigenesis. Front Oncol 12:1\u201311. https:\/\/doi.org\/10.3389\/fonc.2022.832804","journal-title":"Front Oncol"},{"key":"12132_CR94","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1053\/j.gastro.2010.04.054","volume":"139","author":"J Dushay","year":"2010","unstructured":"Dushay J, Chui PC, Gopalakrishnan GS et al (2010) Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease. Gastroenterology 139:456\u2013463. https:\/\/doi.org\/10.1053\/j.gastro.2010.04.054","journal-title":"Gastroenterology"},{"key":"12132_CR95","doi-asserted-by":"publisher","first-page":"e50524","DOI":"10.7759\/cureus.50524","volume":"15","author":"S Bahijri","year":"2023","unstructured":"Bahijri S, Eldakhakhny B, Enani S et al (2023) Fibroblast growth factor 21: A more effective biomarker than free fatty acids and other insulin sensitivity measures for predicting non-alcoholic fatty liver disease in Saudi Arabian Type 2 diabetes patients. Cureus 15:e50524. https:\/\/doi.org\/10.7759\/cureus.50524","journal-title":"Cureus"},{"key":"12132_CR96","doi-asserted-by":"publisher","first-page":"E18","DOI":"10.1152\/ajpendo.00138.2025","volume":"329","author":"H Mori","year":"2025","unstructured":"Mori H, Inoue K, Matsui S et al (2025) Promotion of obesity by fibroblast growth factor 21-oxytocin system dysfunction due to sugar-specific hyperphagia. Am J Physiol - Endocrinol Metab 329:E18\u2013E24. https:\/\/doi.org\/10.1152\/ajpendo.00138.2025","journal-title":"Am J Physiol - Endocrinol Metab"},{"key":"12132_CR97","doi-asserted-by":"publisher","first-page":"117608","DOI":"10.1016\/j.biopha.2024.117608","volume":"180","author":"M Meroni","year":"2024","unstructured":"Meroni M, Dongiovanni P, Tiano F et al (2024) \u03b2-Klotho as novel therapeutic target in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A narrative review. Biomed Pharmacother 180:117608. https:\/\/doi.org\/10.1016\/j.biopha.2024.117608","journal-title":"Biomed Pharmacother"},{"key":"12132_CR98","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1111\/j.1365-2796.2011.02466.x","volume":"270","author":"C G\u00e4lman","year":"2011","unstructured":"G\u00e4lman C, Angelin B, Rudling M (2011) Pronounced variation in bile acid synthesis in humans is related to gender, hypertriglyceridaemia and circulating levels of fibroblast growth factor 19. J Intern Med 270:580\u2013588. https:\/\/doi.org\/10.1111\/j.1365-2796.2011.02466.x","journal-title":"J Intern Med"},{"key":"12132_CR99","doi-asserted-by":"crossref","unstructured":"Kaur N, Gare SR, Shen J et al (2022) Multi-organ FGF21-FGFR1 signaling in metabolic health and disease. Front Cardiovasc Med Volume 9-","DOI":"10.3389\/fcvm.2022.962561"},{"key":"12132_CR100","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.3390\/antiox12071449","volume":"12","author":"S Cinti","year":"2023","unstructured":"Cinti S (2023) Obese adipocytes have altered redox homeostasis with metabolic consequences. Antioxidants 12:1449","journal-title":"Antioxidants"},{"key":"12132_CR101","doi-asserted-by":"publisher","first-page":"2414919","DOI":"10.1080\/21623945.2024.2414919","volume":"13","author":"IA Odeniyi","year":"2024","unstructured":"Odeniyi IA, Ahmed B, Anbiah B et al (2024) An improved in vitro 3T3-L1 adipocyte model of inflammation and insulin resistance. Adipocyte 13:2414919. https:\/\/doi.org\/10.1080\/21623945.2024.2414919","journal-title":"Adipocyte"},{"key":"12132_CR102","first-page":"463","volume-title":"The Mechanism of Leptin Resistance in Obesity and Therapeutic Perspective BT - Obesity and Lipotoxicity","author":"A Engin","year":"2024","unstructured":"Engin A (2024) In: ENGIN AB, ENGIN A (eds) The mechanism of leptin resistance in obesity and therapeutic perspective BT - obesity and lipotoxicity. Springer International Publishing, Cham, pp 463\u2013487"},{"key":"12132_CR103","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.metabol.2017.04.005","volume":"72","author":"D Thomas","year":"2017","unstructured":"Thomas D, Apovian C (2017) Macrophage functions in lean and obese adipose tissue. Metabolism 72:120\u2013143. https:\/\/doi.org\/10.1016\/j.metabol.2017.04.005","journal-title":"Metabolism"},{"key":"12132_CR104","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.cmet.2016.02.001","volume":"23","author":"S Talukdar","year":"2016","unstructured":"Talukdar S, Zhou Y, Li D et al (2016) A long-acting FGF21 molecule, PF-05231023, decreases body weight and improves lipid profile in non-human primates and type 2 diabetic subjects. Cell Metab 23:427\u2013440. https:\/\/doi.org\/10.1016\/j.cmet.2016.02.001","journal-title":"Cell Metab"},{"key":"12132_CR105","doi-asserted-by":"publisher","first-page":"2705","DOI":"10.1016\/S0140-6736(18)31785-9","volume":"392","author":"A Sanyal","year":"2018","unstructured":"Sanyal A, Charles ED, Neuschwander-Tetri BA et al (2018) Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial. Lancet 392:2705\u20132717. https:\/\/doi.org\/10.1016\/S0140-6736(18)31785-9","journal-title":"Lancet"},{"key":"12132_CR106","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1111\/bph.15725","volume":"179","author":"EJ Tillman","year":"2022","unstructured":"Tillman EJ, Brock WJ, Rolph T (2022) Efruxifermin, a long-acting Fc-fusion FGF21 analogue, reduces body weight gain but does not increase sympathetic tone or urine volume in Sprague Dawley rats. Br J Pharmacol 179:1384\u20131394. https:\/\/doi.org\/10.1111\/bph.15725","journal-title":"Br J Pharmacol"},{"key":"12132_CR107","doi-asserted-by":"crossref","unstructured":"Li S, Zou W, Zhou Y et al (2025) A systematic review and meta-analysis of efruxifermin\u2019s efficacy in improving liver fibrosis in patients with NASH\/MASH. Front Pharmacol Volume 16","DOI":"10.3389\/fphar.2025.1594091"},{"key":"12132_CR108","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/s10928-016-9481-1","volume":"43","author":"WC Thompson","year":"2016","unstructured":"Thompson WC, Zhou Y, Talukdar S, Musante CJ (2016) PF-05231023, a long-acting FGF21 analogue, decreases body weight by reduction of food intake in non-human primates. J Pharmacokinet Pharmacodyn 43:411\u2013425. https:\/\/doi.org\/10.1007\/s10928-016-9481-1","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"12132_CR109","doi-asserted-by":"publisher","unstructured":"Headland ML, Clifton PM, Keogh JB (2019) Effects of weight loss on FGF-21 in human subjects: An exploratory study. Int J Environ Res Public Health 16. https:\/\/doi.org\/10.3390\/ijerph16234877","DOI":"10.3390\/ijerph16234877"},{"key":"12132_CR110","doi-asserted-by":"publisher","first-page":"254S","DOI":"10.3945\/ajcn.2009.28449B","volume":"91","author":"SA Kliewer","year":"2010","unstructured":"Kliewer SA, Mangelsdorf DJ (2010) Fibroblast growth factor 21: from pharmacology to physiology. Am J Clin Nutr 91:254S\u2013257S. https:\/\/doi.org\/10.3945\/ajcn.2009.28449B","journal-title":"Am J Clin Nutr"},{"key":"12132_CR111","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1002\/oby.22344","volume":"27","author":"ED Charles","year":"2019","unstructured":"Charles ED, Neuschwander-Tetri BA, Pablo Frias J et al (2019) Pegbelfermin (BMS-986036), PEGylated FGF21, in patients with obesity and type 2 diabetes: Results from a randomized phase 2 study. Obes (Silver Spring) 27:41\u201349. https:\/\/doi.org\/10.1002\/oby.22344","journal-title":"Obes (Silver Spring)"},{"key":"12132_CR112","doi-asserted-by":"publisher","first-page":"3143","DOI":"10.1073\/pnas.1200797109","volume":"109","author":"W Wei","year":"2012","unstructured":"Wei W, Dutchak PA, Wang X et al (2012) Fibroblast growth factor 21 promotes bone loss by potentiating the effects of peroxisome proliferator-activated receptor \u03b3. Proc Natl Acad Sci U S A 109:3143\u20133148. https:\/\/doi.org\/10.1073\/pnas.1200797109","journal-title":"Proc Natl Acad Sci U S A"},{"key":"12132_CR113","doi-asserted-by":"publisher","unstructured":"Liu J, Jiang J, Li Y et al (2024) Effects of FGF21 overexpression in osteoporosis and bone mineral density: a two-sample, mediating Mendelian analysis. Front Endocrinol (Lausanne) Volume 15. https:\/\/doi.org\/10.3389\/fendo.2024.1439255","DOI":"10.3389\/fendo.2024.1439255"},{"key":"12132_CR114","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1056\/NEJMoa2304286","volume":"389","author":"L Rohit","year":"2023","unstructured":"Rohit L, J. SA VKK et al (2023) Randomized, controlled trial of the FGF21 analogue pegozafermin in NASH. N Engl J Med 389:998\u20131008. https:\/\/doi.org\/10.1056\/NEJMoa2304286","journal-title":"N Engl J Med"},{"key":"12132_CR115","doi-asserted-by":"publisher","first-page":"9943228","DOI":"10.1155\/ije\/9943228","volume":"2025","author":"Z Nie","year":"2025","unstructured":"Nie Z, Xu J, Liu Y et al (2025) Effects and Safety of FGF21 Analogs on Glycemic Parameters, Lipid Profiles, and Adiponectin in Overweight and Obese Adults: A Meta-Analysis of Randomized Controlled Trials. Int J Endocrinol 2025:9943228. https:\/\/doi.org\/10.1155\/ije\/9943228","journal-title":"Int J Endocrinol"},{"key":"12132_CR116","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.jare.2020.05.020","volume":"24","author":"M Saber-Ayad","year":"2020","unstructured":"Saber-Ayad M, Hammoudeh S, Radwan H et al (2020) The FGF-21 genetic variants rs838133 and rs838145 are associated with high salt intake in the Emirati population. J Adv Res 24:485\u2013494. https:\/\/doi.org\/10.1016\/j.jare.2020.05.020","journal-title":"J Adv Res"},{"key":"12132_CR117","doi-asserted-by":"publisher","unstructured":"Dai M, Li Y, Zhang J et al (2025) Genetic polymorphisms associated with metabolic dysfunction-associated steatotic liver disease and cardiometabolic risk susceptibility in the Chinese Han population. Hum Genomics 19. https:\/\/doi.org\/10.1186\/s40246-025-00834-6","DOI":"10.1186\/s40246-025-00834-6"},{"key":"12132_CR118","doi-asserted-by":"publisher","first-page":"7847","DOI":"10.18632\/aging.102293","volume":"11","author":"F Ji","year":"2019","unstructured":"Ji F, Liu Y, Hao J-G et al (2019) KLB gene polymorphism is associated with obesity and non-alcoholic fatty liver disease in the Han Chinese. Aging 11:7847\u20137858. https:\/\/doi.org\/10.18632\/aging.102293","journal-title":"Aging"},{"key":"12132_CR119","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fendo.2023.1220426","volume":"14","author":"M Yang","year":"2023","unstructured":"Yang M, Liu C, Jiang N et al (2023) Fibroblast growth factor 21 in metabolic syndrome. Front Endocrinol (Lausanne) 14:1\u201310. https:\/\/doi.org\/10.3389\/fendo.2023.1220426","journal-title":"Front Endocrinol (Lausanne)"},{"key":"12132_CR120","doi-asserted-by":"publisher","first-page":"389","DOI":"10.4236\/ijcm.2023.149035","volume":"14","author":"HK Krishnamurthy","year":"2023","unstructured":"Krishnamurthy HK, Reddy S, Jayaraman V et al (2023) Relationship of High Sensitivity C-Reactive Protein with Cardiovascular, Diabetic, and Hepatic Biomarkers. Int J Clin Med 14:389\u2013401. https:\/\/doi.org\/10.4236\/ijcm.2023.149035","journal-title":"Int J Clin Med"},{"key":"12132_CR121","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/biomedicines13020359","volume":"13","author":"S Mukherjee","year":"2025","unstructured":"Mukherjee S, Im SS (2025) Decoding health: Exploring essential biomarkers linked to metabolic dysfunction-associated steatohepatitis and type 2 diabetes mellitus. Biomedicines 13:1\u201313. https:\/\/doi.org\/10.3390\/biomedicines13020359","journal-title":"Biomedicines"},{"key":"12132_CR122","doi-asserted-by":"publisher","first-page":"155530","DOI":"10.1016\/j.metabol.2023.155530","volume":"142","author":"S-S Li","year":"2023","unstructured":"Li S-S, Sheng M, Sun Z-Y et al (2023) Upstream and downstream regulators of Klotho expression in chronic kidney disease. Metabolism 142:155530. https:\/\/doi.org\/10.1016\/j.metabol.2023.155530","journal-title":"Metabolism"},{"key":"12132_CR123","doi-asserted-by":"publisher","first-page":"1454142","DOI":"10.3389\/fimmu.2024.1454142","volume":"15","author":"X Zhao","year":"2024","unstructured":"Zhao X, Han D, Zhao C et al (2024) New insights into the role of Klotho in inflammation and fibrosis: molecular and cellular mechanisms. Front Immunol 15:1454142. https:\/\/doi.org\/10.3389\/fimmu.2024.1454142","journal-title":"Front Immunol"},{"key":"12132_CR124","doi-asserted-by":"publisher","first-page":"449","DOI":"10.5009\/gnl17443","volume":"12","author":"KJ Lee","year":"2018","unstructured":"Lee KJ, Jang YO, Cha S-K et al (2018) Expression of fibroblast growth factor 21 and \u03b2-Klotho regulates hepatic fibrosis through the nuclear factor-\u03baB and c-Jun N-terminal kinase pathways. Gut Liver 12:449\u2013456. https:\/\/doi.org\/10.5009\/gnl17443","journal-title":"Gut Liver"},{"key":"12132_CR125","doi-asserted-by":"publisher","first-page":"155137","DOI":"10.1016\/j.metabol.2022.155137","volume":"129","author":"M Porflitt-Rodr\u00edguez","year":"2022","unstructured":"Porflitt-Rodr\u00edguez M, Guzm\u00e1n-Arriagada V, Sandoval-Valderrama R et al (2022) Effects of aerobic exercise on fibroblast growth factor 21 in overweight and obesity. A systematic review. Metabolism 129:155137. https:\/\/doi.org\/10.1016\/j.metabol.2022.155137","journal-title":"Metabolism"},{"key":"12132_CR126","doi-asserted-by":"publisher","first-page":"3838","DOI":"10.1038\/s41467-021-24074-z","volume":"12","author":"A Martin","year":"2021","unstructured":"Martin A, Ecklu-Mensah G, Ha CWY et al (2021) Gut microbiota mediate the FGF21 adaptive stress response to chronic dietary protein-restriction in mice. Nat Commun 12:3838. https:\/\/doi.org\/10.1038\/s41467-021-24074-z","journal-title":"Nat Commun"},{"key":"12132_CR127","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1038\/s41591-021-01425-3","volume":"27","author":"SA Harrison","year":"2021","unstructured":"Harrison SA, Ruane PJ, Freilich BL et al (2021) Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial. Nat Med 27:1262\u20131271. https:\/\/doi.org\/10.1038\/s41591-021-01425-3","journal-title":"Nat Med"},{"key":"12132_CR128","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1038\/s41591-023-02427-z","volume":"29","author":"DL Bhatt","year":"2023","unstructured":"Bhatt DL, Bays HE, Miller M et al (2023) The FGF21 analog pegozafermin in severe hypertriglyceridemia: a randomized phase 2 trial. Nat Med 29:1782\u20131792. https:\/\/doi.org\/10.1038\/s41591-023-02427-z","journal-title":"Nat Med"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12132-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-026-12132-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12132-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T11:18:00Z","timestamp":1781781480000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-026-12132-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,18]]},"references-count":128,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["12132"],"URL":"https:\/\/doi.org\/10.1007\/s11033-026-12132-y","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,18]]},"assertion":[{"value":"21 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The authors declare that there are no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"It is a review and no ethical approval is required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Ethical statements"}},{"value":"Not Applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}},{"value":"Not Applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Animal ethical approval"}}],"article-number":"943"}}